CTLT / Catalent, Inc. (CTLT) Q3 2023 Business Update Transcript

Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported more_horizontal

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock. more_horizontal

Elliott recently entered a cooperation agreement with Catalent. This could pave the way for some major changes at the pharmaceutical company. more_horizontal

Drug manufacturer Catalent Inc. CTLT, +1.74% said Friday it has received a notice from the New York Stock Exchange informing it that's it's not in com more_horizontal

The company delivered a better-than-expected quarterly earnings report. It beat on revenue, and only narrowly missed on earnings. more_horizontal

Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and more_horizontal

The contract drug manufacturer posted steep declines in key fundamentals in its fiscal fourth quarter. Still, it booked more revenue than analysts exp more_horizontal

Catalent, Inc. (NYSE:CTLT ) Q4 2023 Earnings Conference Call August 29, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Re more_horizontal